244 results about "Slow Virus Diseases" patented technology

The invention belongs to the field of allogenic mesenchymal stem cells, and particularly relates to a preparation method of allogenic mesenchymal stem cells by CRISPR (clustered regularly interspaced short palindromic repeats) technique editing and IGF (insulin-like growth factor) optimization and application of the allogenic mesenchymal stem cells in treating myocardial infarction. The preparation method comprises the following steps: carrying out separation by density gradient centrifugation to obtain allogenic single karyocytes, and carrying out adherent culture to obtain mesenchymal stem cells; designing a mesenchymal stem cell surface antigen B2M-gRNA and an inflammatory factor TNF-alpha-gRNA; establishing recombinant slow virus particles, and transfecting the mesenchymal stem cells; optimizing the mesenchymal stem cells by using IGF-1; and preparing drugs for treating myocardial infarctions by using the modified and optimized mesenchymal stem cells. The CRISPR/Cas9 technique is utilized to remove the antigens capable of causing immunological rejection and the inflammatory factors capable of causing inflammatory reaction on the mesenchymal stem cell surface, and the IGF-1 is utilized to enhance the apoptosis resistance of the mesenchymal stem cells and promote the homing of the mesenchymal stem cells, thereby providing a new technical scheme for preparing drugs for treating cardiovascular diseases in clinic. The prepared allogenic mesenchymal stem cells can not cause immunological rejection after cell transplantation.

The invention discloses a targeted-FTO-gene-knockout sgRNA (small guide ribonucleic acid) and CRISP (clustered regularly interspaced short palindromic repeats)/Cas9 slow virus system and application thereof. The sgRNA is selected from FTOsgRNAsp2 or FTOsgRNAsp3 with the following DNA sequence. The sgRNA has high cutting efficiency for the FTO gene. When the sgRNA-containing CRISPR/Cas9 slow virus system is used for transfecting SV-HUC-1, the FTO protein expression level of the obtained cell strain is obviously lowered. Therefore, the sgRNA disclosed by the invention can effectively implement targeted FTO gene knockout; and after the sgRNA is established into the CRISPR/Cas9 slow virus system, the system can knock out the FTO gene to obtain the FTO-gene-knockout cell strain, thereby being beneficial to researching the action mechanism of FTO in the cell strain.

The invention provides a method for efficiently inducing multipotential stem cells, six inducible factors such as Oct4 (POU5f1), Sox2, c-Myc, Klf4, UFT1, Rex1 (ZFP42), and the like and p53 gene inhibitor are induced into the cells by utilizing a slow virus carrier, thereby the method can efficiently induce and produce the multipotential stem cells.

The invention discloses a low-expression CYP7A1 hepatic cell and a constructing method thereof. A method for inhibiting the CYP7A1 expression level of the hepatic cell comprises the step of introducing an encoding gene of small-interference RNA which is used for inhibiting the CYP7A1 gene expression into the hepatic cell so as to inhibit the CYP7A1 expression level of the hepatic cell. A slow virus vector system can be used for introducing the encoding gene of small-interference RNA which is used for inhibiting the CYP7A1 gene expression into the hepatic cell. An experiment proves that the method of the invention can obviously regulate the expression level of the CYP7A1 gene of the hepatic cell in an mRNA level and a protein level downwards and can further effectively reduce the secretoryvolume of total bile acid. The Low-expression CYP7A1 hepatic cell and the constructing method thereof can be used for the fundamental research and the clinical application of biologic artificial liver supporting treatment and have a wide application prospect.

The invention relates to a method of inducing a human fibroblast to reprogram the human fibroblast into an osteoblast by utilization of Runx2 and a low-molecular-weight compound, particularly relates to a method of inducing a human fibroblast to transdifferentiate the human fibroblast into an osteoblast under the existence of dexamethasone by utilization of Runx2 gene expression, a low-molecular-weight compound CHIR99021 and/or a low-molecular-weight compound forskolin, and belongs to the fields of cytobiology and tissue engineering. The method includes: constructing a human skin fibroblast infected by a slow virus carrying Runx2-GFP, performing transdifferentiation of the human fibroblast under the existence of the dexamethasone by utilization of the low-molecular-weight compound CHIR99021 having a concentration of 5-10 muM and the low-molecular-weight compound forskolin having a concentration of 10 muM, changing into an osteoblast inducing liquid after 7-15 days, and inducing, and the fibroblast can be induced into the osteoblast after 5-20 days. The method can obtain osteoblasts simply and rapidly and can be used for cell therapy for bone metabolic disease, fracture, and the like. A pharmaceutical composition provided by the invention can be used for research, development and production of tissue-engineered bone, brings convenience to fundamental research and brings a prospect for clinical application.

The invention discloses an immortalized human liver cell line, a preparation method and an application thereof. The immortalized human liver cell line has the main function of primarily cultured humanliver cell. The preparation method comprises the following steps of: transferring SV40T antigen and human telomerase catalyzed subunit gene into primarily cultured separated human normal liver cell by slow virus carrier; and sieving in a cloning way to obtain the immortalized human liver cell line. The immortalized human liver cell line also can be extrinsically amplified in large scales in a microcarrier way. The immortalized human liver cell line can be used for preparing a biological artificial liver support system and preparing the medicament for curing the liver failure.

The invention belongs to the biomedicine field, and aims at providing an expression vector for stably indicating cell autophagy activities, an establishing method and an application method thereof. By constructing a slow-virus expression plasmid containing an EGFP-LC3 autophagy reporter gene and adopting a four-plasmid system, the invention establishes a slow-virus expression vector capable of enabling cells to stably express an EGFP-LC3 gene. By using the expression vector to infect a host cell, the EGFP-LC3 gene can be stably integrated in a genome of the host cell, and the host cell can stably and efficiently express the EGFP-LC3 and indicate cell autophagy changes. A stable autophagy indicating cell can be established by using the expression vector, and the cell autophagy changes are quickly and quantitatively analyzed by an image analysis method based on Top-hat operators and morphological filtration. The invention has the characteristics of stable and reliable autophagy indication, real-time sensitivity, quick and accurate autophagy quantification, simply and convenient operation and the like, greatly facilitates autophagy observation and analysis, and can be widely used for autophagy-correlated researches.

The invention belongs to the gene engineering field and relates to a site-specific integration slow virus vector and a method for preparing the same. The vector system consists of a FattbC31UGW plasmid, CMV delta 8.9-D64N/D116N and an envelope plasmid VSVG. To overcome the risk of insertion mutation caused by random integration of the slow virus vector system, the method remodifies the prior slow virus vector system, and obtains the site-specific integration slow virus vector system through the combination with a phiC31 integrase system. A transgene carried by the virus vector can be steadily integrated on a special site of a host genome. As the novel slow virus vector integrating effectiveness, safety and operation simplicity, on the one hand, the site-specific integration slow virus vector can be used to identify the function of an exogenous gene, in particular the function in genetically modified cell engineering; on the other hand, the method provides safer and more efficient novel approach for gene therapy in fields such as tumor inhibition and virus resistance and so on.

The invention discloses a preparation method of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) cells, the prepared CAR-T cells and application thereof. The preparation method comprises the following steps: S1, separating, activating and amplifying T lymphocytes: after activating separated CD3+CD8+T lymphocytes, culturing and amplifying; S2, infecting the T lymphocytes treated in step S1 bya recombinant slow virus carrying a CAR, so as to prepare the CAR-T cells, wherein a CAR gene carried in the recombinant slow virus carrying the CAR comprises a CD28 intracellular domain and a 4-1BBintracellular domain; nucleotide sequences of the CD28 intracellular domain and the 4-1BB intracellular domain are shown as SEQ ID7 and SEQ ID9 respectively. The CAR-T cells prepared by the method canbe widely applied to treatment of various cancers. Compared with the prior art, the proliferation rate of the prepared CAR-T cells is remarkably improved when compared with CAR-T cells prepared by aconventional method.

The invention belongs to the field of biotechnology, particularly relates to a titer detection method for a slow virus carrier, and discloses a quality index detecting method conducting real-time fluorescence quantification nucleic acid amplification detection (qPCR and RT-qPCR) by using a sequence specific primer and a fluorescent dye, a used primer and a standard product. The detecting method isefficient and accurate, the operation is easy, the use amount of a sample is low, the repeatability is good, and the limit problem of inaccurate carrier quantitation in the fields of eucaryon geneticengineering and gene therapy is solved. The method has the advantages of detection time and simple and convenient operation step, the analysis process after the amplification is not needed, comparedwith the Taqman probe method, the SYBR Green I does not need the design of a synthesis fluorescent probe, the design is simplified, the cost is lowered, and a dissolution curve is combined in the analysis to judge the specificity of the reaction.

The invention discloses a preparation method of a pseudotype virus for nucleic acid detection of 2019-nCoV, and relates to the technical field of biology. The preparation method comprises a method forpreparing standard quality control products which contain but are not limited to a 2019-nCoV nucleotide sequence and are used for nucleic acid detection through a non-integrated slow virus vector system, a method which is used for preparing the standard quality control products for nucleic acid detection, and a method for constructing a non-integrated slow virus through mutating 64-locus amino acid Asp of integrase of slow virus auxiliary plasmid into Asn, and amino acids Arg, Arg and Lys at 262-264 loci into Ala, Ala and His. In the manner of removing elements of promoters and the like of slow viruses, the load quantity of virus vectors can be promoted, a pseudotype virus which can be used for nucleic acid detection and complete flow quality control is constructed, and the preparation method can be used for constructing a pseudotype virus for corona viruses and can also be used for constructing a pseudotype virus for SARS-COV, MERS-COV, influenza viruses and the like.

The invention relates to bioengineering technologies, and particularly relates a method of inducing differentiation of neural stem cells into dopaminergic neurons by using recombinant slow virus. The method comprises the following steps: constructing a recombinant slow virus vector; separating, culturing and identifying the neural stem cells; transfecting the recombinant slow virus into NSCs; identifying the NSCs transfected by the recombinant slow virus, wherein the process of transfecting the recombinant slow virus into the NSCs comprises the following steps: digesting NSCs after being subjected to three times of passages to prepare a single-cell suspension, and inoculating into a culture plate; transfecting the TH+Brn4 gene recombinant slow virus; adding the slow virus and ploybrene, uniformly shaking, putting the culture plate into an incubator to culture for 1-2 hours, and replacing fresh differential culture medium; meanwhile, screening by using puromycin to obtain stable transfected cells. The method has the advantages as follows: by constructing the slow virus vectors of target genes TH and Brn4, exogenous genes after transfecting the NSCs can be stably expressed in cells; high proportion of TH positive dopaminergic neuron is generated after differentiation; the Brn4 can promote high expression of neurotrophic factors and has the function of inhibiting apoptosis.

The invention discloses a modified enhanced type DC-CIK cell targeting immune cell mass, and a preparation method and application thereof. A method for preparing a DC cell comprises the following steps: performing isolated culture on monocyte, thereby acquiring an immature DC cell; and performing tumor antigen load and induced differentiation culture on the immature DC cell, thereby acquiring a mature DC cell, wherein the monocyte is acquired by separating from a peripheral blood mononuclear cell of a sample. The method for preparing CIK comprises the following steps: performing in vitro differentiation culture on a CIK cell, thereby acquiring an immature CIK cell; preparing a modifying recombined slow virus for performing in vitro modification on the CIK cell; and co-culturing the modified CIK cell and the DC cell, thereby acquiring the mature modified CIK cell (Triumph-DC-CIK), so as to be used for achieving a better tumor immunotherapy effect.

The invention discloses an inducing method for danio-rerio inductivity multi-potential stem cells. The induction method includes the following steps that danio-rerio tissues or danio-rerio embryos are gotten, and danio-rerio fibroblasts are obtained through in-vitro isolated culturing; the danio-rerio fibroblasts are infected through viruses, the infected danio-rerio fibroblasts are induced, and the danio-rerio inductivity multi-potential stem cells are obtained through manual selecting cloning and subculturing. Based on the same technical scheme, the invention further discloses an inductive culture medium and an iPS culture medium used for the inducing method. RT-PCR analysis indicates that iPS cells induced through the embryo fibroblasts have the potency of being differentiated into various triploblastic-source cells. By means of the method, the inductive culture medium and the iPS culture medium, the technical difficulty that the infection efficiency of slow viruses in fish cells is low is overcome, and new tool cell sources and new concepts are provided for researching a danio-rerio somatic-cell reprogramming mechanism to select cell materials.

The invention discloses a method for establishing a tree-shrew breast cancer model for slow virus by nipple injection. Slow virus is introduced to a tree-shrew breast duct by adopting a nipple injection technology, so that a cancer gene is over-expressed or an anti-cancer gene is knocked down after epithelial cells in a mediated duct are infected, and therefore, tree-shrew breast tumors are induced. According to the method for establishing a tree-shrew breast cancer model for slow virus by nipple injection disclosed by the invention, the breast tumors can be touched within two weeks after expressing the cancer gene PyMT; and moreover, the induction success rate is almost 100%, and the method is short in incubation period, strong in specificity, extremely high in induction rate, stable and convenient and simple to operate. The method disclosed by the invention can be used for quickly and efficiently establishing the tree-shrew breast cancer model.

The invention discloses a natural killer cell modified by specific chimeric antigen receptor gene and a preparation method and use thereof. The natural killer cell modified by specific chimeric antigen receptor gene comprises a NY-ESCO-1 specific chimeric antigen receptor gene and a truncated spleen tyrosine kinase Syk gene. The preparation method simultaneously infects the natural killer cell with a slow virus containing the NY-ESCO-1 specific chimeric antigen receptor gene and a slow virus containing the truncated spleen tyrosine kinase Syk gene. By the combined action of the NY-ESCO-1 specific chimeric antigen receptor gene and the truncated spleen tyrosine kinase Syk gene, the natural killer cell modified by the specific chimeric antigen receptor gene improves the targeted tumor cell specific lethality of the natural killer cell, improves the ability of activating downstream signals of the natural killer cell, avoids the escape of tumor immunity, and accordingly enhances the killing activity on the tumor cell.